Compare · GLP-1 agonist
Mazdutide vs Tirzepatide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Mazdutide | Tirzepatide | |
|---|---|---|
| Evidence | 7/10 | 10/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A GLP-1/glucagon dual agonist approved in China for weight loss and diabetes, with genuine RCT evidence that is still sponsor-funded and single-country. | A dual GIP/GLP-1 receptor agonist with strong RCT evidence for type 2 diabetes, weight loss, and sleep apnea; GI side effects are common. |
| Full profile → | Full profile → |
Mazdutide
Mazdutide is an injectable drug for weight loss and type 2 diabetes that switches on two of the body's metabolic hormone receptors at the same time. Most of the buzzy GLP-1 compounds are still stuck at the press-release stage, but mazdutide is further along: it has a full Phase 3 trial published in…
Tirzepatide
Tirzepatide is a once-a-week injectable peptide. You may know it by its brand names: Mounjaro (for type 2 diabetes) and Zepbound (for weight management and sleep apnea). Most of the compounds we write about here have thin evidence behind them. This one is different: it has been tested in large,…